“Can surgery still matter in metastatic prostate cancer?” 🩺 💥 RAMPP trial says maybe yes - even in low-volume mHSPC. 🧪 Design: De novo low-volume mHSPC (≤5 bone mets ± nodes) 👥 Fit for RP + systemic therapy (ADT ± ARPI) 🆚 Radical prostatectomy (RP) + BST vs BST alone 🎯

📊 Göteborg-1 Trial – 25-Year Follow-up Extended follow-up from the Göteborg-1 screening trial confirms that active surveillance remains a safe and effective long-term strategy for well-selected men with low- and intermediate-risk prostate cancer. 🔹AS shows 94% PC-specific

RAMPP trial out in @EUplatinum. Radical prostatectomy for oligometastic cancer improves cancer specific mortality. Important work.

🚨New episode available! Part 2 of the discussion with @DrRosenbergMSK on the history of IO drug development in urothelial cancer. Don't miss it! 🎙️ GU Oncology Now: https://t.co/11YPPSGiPt  🍎 Apple Podcasts: https://t.co/m76uRqIoWc 🎧Spotify: https://t.co/1VB7hpQYRk

🚀 POPART trial (n=100): Post-op SABR (32.5 Gy/5fx) for BCR after prostatectomy ✅ well-tolerated; late ≥G2 GU 7.5%, GI 1% 📉 2-yr BRFS ~79% (PSA ↓ to 0.028 ng/mL) ➡️SBRT prostate bed salvage = promising, needs longer follow-up. #ASTRO25 #RadOnc @ASTRO_org

🚨 New in European Urology: Consolidative surgery after #EnfortumabVedotin +/– ICI in advanced urothelial carcinoma: ✅ 82% downstaging ✅ 43% ypT0N0 ✅ 79% stopped systemic therapy ✅ 89% DFS in curative group 📄 https://t.co/Yd52YZKRNk #BladderCancer #Immunotherapy #Urology

Thiazides in Stone Prevention Where Do We Stand? A recent NOSTONE trial (NEJM 2023) questioned the value of thiazides for preventing kidney stones. During 3 years, HCT at different doses showed no benefit compared to placebo in reducing stone episodes. At first glance, this

JUST IN: IMvigor011 in muscle-invasive bladder cancer (MIBC) hits both DFS & OS with PD-L1 inhibitor Atezolizumab in ctDNA+ population. Major news for Precision Oncology in adjuvant Solid Cancers! @NateraGenetics @tompowles1 @Roche https://t.co/OlOirNfWHo

In the future we won’t rely on pathology at surgery +/- luck to select patients for adjuvant treatment across cancers. Instead, the identification of residual disease by ctDNA/other biomarkers will be used. These data are a step towards that goal IMO. https://t.co/dPqlvr2rnV

IMVIGOR011: Atezo vs placebo in ctDNA+ve bladder ca (including -ve becoming +ve) post cystectomy hit OS/PFS. It also tracks outcomes in the ctDNA-ve, supporting a ctDNA adjusted approach. It’s been a long journey for atezo in UC but it has +ve OS at last https://t.co/dPqlvr2rnV

How to crush a PSMA PET report: Guidelines and scoring systems. Presentation by Phillip Kuo, MD, PhD, FACR @cityofhope addressing standardized PSMA PET reporting across clinical and research contexts. #WatchNow > https://t.co/ekrjJzPKHo @PSMAconference #2025PSMAandBeyond

#FansofFANS - To sit or stand? Find out in our paper below⬇️ https://t.co/EAFDXAdYfZ @DocGauhar @steffiyuen @D_Castellani @endouro @jl_kwok @soebhali @OTRAXER @sbinhamrii @lazarostzelves #UroSoMe @JEndourology

Access the full paper on PSMA-PET prognostic and predictive biomarkers in ENZAp with the link below: @ANZUPtrials @LancetOncology @TrialsCentre @MovemberAUS @PCFnews https://t.co/o68IVgEODX

The Gleason score - the fundamental determinant of how we chose on treatments in localized prostate cancers - basically doesn't make any sense.

📢 European Urology editorial by J.A. Witjes: Alternating cystoscopy with urinary markers (XBCM, BE) in HG-NMIBC follow-up is safe, cost-effective, and may detect recurrences earlier. 🧪 “The future has arrived.” 🔗 https://t.co/RKaXR8wCZ2 #BladderCancer #UroOnc #NMIBC #EAU25

With the final analysis of the last of the 1st line metastatic clear cell RCC trials combination trials it’s still fair to say ‘pick one and use it well’. #GUARDSymposium2025 Ipi/nivo is less good at getting initial control but has less long term toxicity. @brian_rini @OncoAlert

🚨 NEW #PlatinumOpinion in European Urology by M. J. Roberts, @GGandaglia et al : 💡 Is extended pelvic lymph node dissection (ePLND) still justified in prostate cancer? 📉 No oncologic benefit in RCTs ⚠️ Up to 20% complication rate 🧬 PSMA PET reshapes staging 🔄 2024 EAU

🚨BREAKING: Just received footage of a new dinosaur species living in the human bladder. The little guy 🦖 was rescued and released back into the wild. Endourology never ceases to surprise. #urology #bladderdino

The Wikipedia for landmark Urology research papers #LANDMARK. Level up your knowledge with the minimal effort. Includes key critical appraisal and very concise summaries for practising urologists. 👀 it OUT https://t.co/SzaOu2U9Ih. Great job @BURSTurology #BAUS25 @ESRUrology

Redo🧵 regarding PDS (polydioxanone) surgical sutures. For reasons that will become evident later, it is useful for me to revisit an old 🧵I posted about PDS 3 years ago. We will again go over the properties of PDS, its history, and what each of the sizes are used for. (1/ )